Payload Information
General Information of This Payload
| Payload ID | PAY0RGUGK |
|||||
|---|---|---|---|---|---|---|
| Name | WO2025015586A1, ADC24, Payload |
|||||
| Synonyms |
compound 6
Click to Show/Hide
|
|||||
| Target | Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8) | |||||
| Structure |
|
|||||
| Formula | C25H33N7O3 |
|||||
| Isosmiles | CCCCC(N1OCCCCNC2=C(NCCNC)C(C2=O)=O)=NC3=C1C4=CC=CC=C4N=C3N |
|||||
| InChI |
InChI=1S/C25H33N7O3/c1-3-4-11-18-31-21-22(16-9-5-6-10-17(16)30-25(21)26)32(18)35-15-8-7-12-28-19-20(24(34)23(19)33)29-14-13-27-2/h5-6,9-10,27-29H,3-4,7-8,11-15H2,1-2H3,(H2,26,30)
|
|||||
| InChIKey |
NHNKZRYLKNNFFA-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
479.585 |
Polar area |
136.19 |
||
Complexity |
1332.591067 |
xlogp Value |
2.0575 |
|||
Heavy Count |
35 |
Rot Bonds |
14 |
|||
Hbond acc |
10 |
Hbond Donor |
4 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| The minimum effective concentration (MEC) | 0.0457 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 0.0457 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 0.137 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 0.137 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2023232144A1ADC28 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) | > 50% | Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC28 was tested in mouse M38 CRC model in C57BL/6 mice, 3 mg/kg, QWx3, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
isumab01-C6 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.002 pM
|
High FRa expression (FRa +++) | ||
| Method Description |
A Cell line test on Colo205
|
||||
| In Vitro Model | Colon adenocarcinoma | Colo205 cells | CVCL_0218 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
8 pM
|
High FRa expression (FRa +++) | ||
| Method Description |
A Cell line test on H2110
|
||||
| In Vitro Model | Lung non-small cell carcinoma | H2110 cells | CVCL_1530 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9 pM
|
High FRa expression (FRa +++) | ||
| Method Description |
A Cell line test on Jeg3
|
||||
| In Vitro Model | Gestational choriocarcinoma | Jeg3 cells | CVCL_0363 | ||
References